tbuckley/cabot-search huggingface dataset:
FRI0134 Risk of Virus-Associated Malignancies in Female Arthritis Patients Treated with Biological DMARDs:
Authors: R.L. Cordtz, L. Mellemkjær, B. Glintborg, M.L. Hetland, O.R. Madsen, L. Dreyer
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Immunosuppressed cohorts experience an increased risk of Human Papilloma Virus (HPV) and other virus-associated malignancies (e.g. Hodgkins and non-Hodgkins lymphoma). Medication exposure may play a role. <h3>Objectives</h3> To investigate the risk of HPV and other virus-associated malignancies in female arthritis patients treated with biological Disease Modifying Anti-Rheumatic drugs (bDMARDs) compared with 1) bDMARD naïve patients and 2) the general population. <h3>Methods</h3> A cohort of 13 905 female arthritis patients (median age 54.8 years, interquartile range 43.1-65.1) with rheumatoid arthritis (72%), psoriatic arthritis (12%), ankylosing spondylitis (4%) or other arthritides (12%) registered in the nationwide DANBIO registry was followed up for any virus-associated malignancy<sup>1</sup> by linkage to the Danish Cancer Registry (DCR), 2000-2011 according to bDMARD exposure. Cumulated follow-up time was 34 429 years. Using Cox regression analysis, hazard ratios (HR) for cancer in ever (N=5647) vs. never (N=10 331) bDMARD treated patients were calculated. In order to compare the incidence with that of the general population, standardized incidence ratios (SIR) were calculated. <h3>Results</h3> HRs for virus-associated malignancies in bDMARD treated vs bDMARD naïve are presented in the Table. Compared with the general population, risk of cervical cancer was neither increased in ever (SIR 1.0, 95% CI 0.3-3.1) nor in never bDMARD-treated patients (SIR 1.1, 95% CI 0.5-2.5). Compared with the general population, SIR of non-Hodgkin9s lymphoma was increased in bDMARD treated (1.54, 95% CI 0.6-3.4) and bDMARD naïve patients (1.7, 95% CI 1.0-3.0). For Hodgkin9s lymphoma, the SIR was increased among bDMARD treated (3.1, 95% CI 0.4-21.7) and reached statistical significance for bDMARD naïve (5.6, 95% CI 1.8-17.3). <h3>Conclusions</h3> In this cohort study including 13 905 female arthritis patients, no overall increased risk of virus-associated cancers in bDMARD-treated compared with never bDMARD-treated arthritis patients was found. However, the observed predominance of anal and oropharyngeal cancers in bDMARD-treated patients needs further investigation. Interestingly, we did not find the risk of cervical cancer to be increased compared with the general population. The risk of lymphomas was increased, but this was not associated with bDMARD-treatment per se. <h3>References</h3> IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. A review of human carcinogens. Part B: Biological agents 100B (2012). <h3>Acknowledgements</h3> Thanks to departments of rheumatology in Denmark for reporting to the DANBIO registry and to The Danish Rheumatism Association and the Danish Cancer Society for financial support. <h3>Disclosure of Interest</h3> None declared
Family histories of depressed and severely anxious children
Authors: R Livingston, H Nugent, L Rader, G R Smith
Journal: American Journal of Psychiatry (1985)

Of 127 relatives of 12 anxious and 11 depressed children, 72% received Family History RDC diagnoses, most commonly depression and alcoholism. The family histories of the two groups were similar, suggesting that childhood depressive and anxiety disorders may be familially related.
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells
Authors: Seongseok Yun, Nicole D. Vincelette, Katherine L. B. Knorr, Luciana L. Almada, Paula A. Schneider, Kevin L. Peterson, Karen S. Flatten, Haiming Dai, Keith W. Pratz, Allan D. Hess, B. Douglas Smith, Judith E. Karp, Andrea E. Wahner Hendrickson, Martin E. Fernandez-Zapico, Scott H. Kaufmann
Journal: Blood (2016)
Safety and efficacy of low-dose pegfilgrastim (pegfil) in maintaining chemotherapy (CT) dose density in patients (pts) receiving docetaxel/doxorubicin/cyclophosphamide (TAC) or doxorubicin/cyclophosphamide (AC) as neoadjuvant chemotherapy (NCT) for stage II-III breast cancer (BC).
Authors: E. Kim, R. Jin, K. Choi, P. H. Frankel, G. Somlo
Journal: Journal of Clinical Oncology (2010)

e19561 Background: The recommended and FDA-approved dose of pegfil is 6mg given every 2 weeks subcutaneously on the day following CT. While well-tolerated in general, constitutional and musculoskeletal side effects represent a challenge. We present our experience using a reduced dose of pegfil in pts experiencing pegfil related side-effects during a phase II study assessing NCT for pts with stage II-III BC. Methods: Retrospective review of laboratory values, CT schedules, and adverse effects for pts under study from 2005 to 2009 was performed. We evaluated pts during their first 6 courses of their planned NCT with doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2, and docetaxel 75 mg/m2 (TAC), or 4 cycles of A 60 mg/m2 and C 600 mg/m2 (AC), plus pegfil. The primary endpoint was the percentage of pts able to maintain dose-density. Other factors investigated included neutrophil count, adverse effects, causes for CT delay, and reasons for decreasing pegfil dose. Results: 12 of 117 pts who received the standard 6 mg pegfil during the first cycle, received 3 mg of pegfil starting with the second cycle due to bone pain (7/12 pts), joint pain (1/12 pts), or muscle pain (4/12 pts). 1 of 12 pts received TAC while 11 pts received AC. Reduced dose pegfil was administered for a median of 1.5 cycles (range 1-5), for a total of 24 cycles, comprising 54 administrations of CT. Statistically significant differences were not found in rates of CT delay between pts who received 6 mg versus 3 mg pegfil. No cycles of CT were delayed due to neutropenia. 4 of 7 pts with prior bone pain no longer reported bone pain on the reduced dose of 3mg pegfil, the 1 case of joint pain resolved, and half (2/4) of the pts whose pegfil was reduced for muscle pain no longer reported muscle pain when treated with 3 mg. Conclusions: The dose of 3 mg may be considered for pts experiencing adverse effects from pegfil such as bone pain and myalgia during dose dense CT. In this limited number of pts we did not observe neutropenia-related treatment delays with 3 mg pegfil following TAC or dose-dense AC. No significant financial relationships to disclose.
Assessment of viable splenic tissue in massive splenic infarction with a Tc-99m heat-damaged RBC scan.
Authors: MARC HICKESON, VILMA DERBEKYAN, ROBERT LISBONA, JAVIER NOVALES-DIAZ
Journal: Clinical Nuclear Medicine (2001)

A 59-year-old man with essential thrombocytosis was examined for abdominal pain. Splenic infarction was diagnosed on a computed tomographic scan. The Tc-99m heat-denatured RBC scan showed viable splenic tissue that was not evident on the computed tomographic scan or Tc-99m sulfur colloid scintigraphy.
Evaluation of a Tubeless Pancreatic Function Test in Patients with Steatorrhoea in a District General Hospital
Authors: S R Gould, G L Chinn, B T Nobbs, G A Lewis
Journal: Journal of the Royal Society of Medicine (1988)

The Pancreolauryl Test (PLT), a tubeless pancreatic function test, has been evaluated in an unselected series of outpatients with steatorrhoea presenting to a district general hospital (DGH). This is the first study of the PLT in a DGH, involving an unselected series of patients and not those from secondary or tertiary referral hospitals. Health controls (n = 15) and patients with self-limiting diarrhoea (n = 8) had normal urinary excretion indices (greater than or equal to 30). Coeliac disease (n = 13) and small bowel bacterial overgrowth (n = 12) were the commonest causes of steatorrhoea and there were no false-positive results in these patients. The mean urinary excretion index in patients with untreated coeliac disease (mean index = 38%) was lower than in healthy controls (n = 15, mean index = 53%; P less than 0.05 greater than 0.02). No patient with proven pancreatic steatorrhoea had a normal PLT result, confirming the high negative predictive value found by others. Low results in patients with steatorrhoea following gastric surgery indicate poor mixing of food with pancreatic juices. The PLT proved to be a simple, inexpensive and noninvasive outpatient screening test suitable for use in a DGH to exclude a pancreatic origin of steatorrhoea.
A Single Center Phase II Trial Of 90yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease
Authors: Felipe Samaniego, Jorge E Romaguera, Nathan Fowler, Michelle A. Fanale, Jatin J. Shah, Peter McLaughlin, Barbara Pro, Vijairam Selvaraj, Frank K Braun, Rohit Mathur, Lei Feng, Sattva Neelapu, Larry W. Kwak
Journal: Blood (2013)
Histopathology of Carcinogenesis and Tumors of the Liver in Rats&lt;xref ref-type="fn" rid="fn1"&gt;1&lt;/xref&gt;
Authors: Firminger, Harlan I.
Journal: JNCI Journal of the National Cancer Institute (1955)

Journal Article Histopathology of Carcinogenesis and Tumors of the Liver in Rats Get access Harlan I. Firminger Harlan I. Firminger Associate Professor of Pathology and Oncology University of Kansas Medical Center, Kansas City, Kansas Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue Supplement_5, April 1955, Pages 1427–1442, https://doi.org/10.1093/jnci/15.Supplement_5.1427 Published: 01 April 1955
AB0608 Greater Organ Involvement and Disease Activity in Childhood-Onset than Adult-Onset With SLE (DATA from Reuma.Pt/Les): Table 1.
Authors: S.I. Sousa, M.J. Gonçalves, L. Inês, G. Eugénio, D. Jesus, S. Fernandes, G. Terroso, V. Romão, M. Cerqueira, A. Raposo, M. Couto, P. Nero, G. Sequeira, T. Novoa, J. Melo Gomes, J. Canas da Silva, L. Costa, C. Macieira, C. Silva, J. Pereira da Silva, H. Canhão, M.J. Santos
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a multi-organ immune-mediated disease that affects predominantly women at reproductive age but may present itself at any age. Age at disease onset has a strong modulating effect on clinical presentation and course of disease. Although young patients may have a more aggressive disease, controversies persist regarding the impact of age at disease onset on SLE outcome. <h3>Objectives</h3> Characterize childhood-onset, adult-onset and late-onset SLE and assess whether disease outcome differs in these three patient groups. <h3>Methods</h3> Patients with childhood-onset (diagnosis ≤18 years) SLE fulfilling ACR 1997 criteria were identified in the Portuguese registry Reuma.pt/SLE and compared with adult-onset (≥19y and ≤49 years) and late-onset (≥50 years) SLE patients paired for disease duration. <h3>Results</h3> Two hundred and sixty seven SLE patients with mean disease duration of 11.9±9.3 years were analyzed (Table 1). The number of fulfilled ACR criteria was significantly higher in childhood-onset SLE. A greater proportion of women, higher prevalence of arthritis and anti-SSA antibodies were noted in the adult-onset group. Hypertension, diabetes and thyroid disease were significantly more prevalent in late-onset SLE. Disease activity at last visit evaluated using the SLEDAI-2K was significantly higher in childhood-onset group than in the late-onset counterparts. SLICC/ACR damage index was numerically higher in late-onset SLE and significantly more patients in this group had irreversible damage. Cyclophosphamide and mycophenolate mophetil were used more frequently in childhood-onset SLE patients. <h3>Conclusions</h3> The skin, kidney and neurological involvement are most common in childhood-onset, as well as the use of immunosuppressants, supporting the concept of a more severe disease. In contrast, patients with late-onset SLE have more comorbidities and irreversible damage. The age of SLE onset has a significant impact not only on the clinical characteristics and disease activity, but is also important for disease outcome. <h3>Disclosure of Interest</h3> None declared
Remission of Essential Hypertension after Renal Transplantation
Journal: New England Journal of Medicine (1984)

Six patients in whom essential hypertension led to nephrosclerosis and kidney failure received kidney transplants from normotensive donors. After an average follow-up of 4.5 years, all were normotensive and had evidence of reversal of hypertensive damage to the heart and retinal vessels. These six patients, all of whom were black, and six control subjects matched for age, sex, and race were admitted to the General Clinical Research Center for 11 days for observation of their blood pressure and their responses to salt deprivation and salt loading. Mean arterial pressure (±S.E.M.) among the patients who had previously had essential hypertension was similar to that of the normal controls (92±1.9 vs. 94±3.9; P not significant), and both groups had similar responses to salt deprivation and salt loading. Thus, essential hypertension in human beings is shown to be similar to the hypertension seen in spontaneously hypertensive rats in that both can be corrected by transplantation of a kidney from a normotensive donor. This observation supports the concept of the primacy of the kidney in causing essential hypertension.
SP0046 Barriers to Health Care in Ethnic Minority Patients with Rheumatic and Musculoskeletal Diseases
Authors: H.A. Zangi
Journal: Annals of the Rheumatic Diseases (2015)

In most European countries the number of immigrants and ethnic minorities are increasing. Ethnic disparities in health care and health outcomes in patients with rheumatic diseases have been described. Recent research has focussed on barriers to health care as a factor contributing to and maintaining health disparities. These barriers occur on system-level, provider-level and individual/patient-level. Barriers may vary from country to country and between ethnic groups. Access to health care for ethnic minority patients may be restricted because of lack of familiarity with the country9s health care system and/or lack of health insurance. Delay in help-seeking among ethnic minorities has been described. Moreover, undocumented immigrants may not be entitled to mainstream health services. Language barriers may lead to inadequate communication between patients and clinicians, less satisfaction and poor coordination of health care. Patients with low language proficiency may be unable to communicate their health concerns sufficiently, increasing the risk of being misunderstood and misdiagnosed. In several countries the access to trained medical interpreters is scarce. Furthermore, limited health literacy in ethnic minority patients is associated with increased disease severity and functional disability. Cultural barriers include differences in understandings of illness and treatment, different expressions of aetiology, symptoms and pain and different perceptions of the roles of patients and clinicians, as well as general differences in cultural norms, religious practices and customs. These disparities may influence treatment preferences, adherence to therapies, help-seeking behaviour and the patient-provider relationship in general. Some ethnic minority patients fear discrimination based on current and previous experiences, which may lead to mistrust of the health care system and delayed treatment seeking. Discrimination on the part of health care providers may lead to poor quality of care. Awareness of existing barriers is the first step in eliminating disparities in health care for ethnic minority patients with rheumatic diseases. Some interventions have also been proposed, such as improving interpreting services, developing educational programmes and information material for immigrants, training health professionals9 cultural awareness, continuity of care and developing guidelines on the care entitlements of different immigrant groups. <h3>Disclosure of Interest</h3> None declared
PWE-111 Non invasive prediction of oesophageal varices based on transient elastography liver stiffness measurement: Abstract PWE-111 Table 1
Authors: NM Mirza, A Akram, F Sheikh, K Koss
Journal: Gut (2015)

<h3>Introduction</h3> Transient elastography is a promising noninvasive method for assessing advanced fibrosis in patients with chronic liver disease and has a comparable sensitivity and specificity profile to liver biopsy. Variceal bleeding is the most serious complication of advanced liver disease and early recognition is of prime importance to prevent this life-threatening complication. In cirrhotic patients, liver stiffness measurements range from 12.5 to 75.5 kPa. However, the clinical relevance of these values is unknown. This study was carried out to investigate the reliability of predicting varices using transient elastography liver stiffness measurement. <h3>Method</h3> 1500 patients had liver stiffness measurement (LSM) using transient elastography between January 2011–January 2015 at Macclesfield District General Hospital. Patients who had LSM &gt;12 kPa and underwent gastroscopy were included in the study. Specificity, sensitivity, positive and negative predictive values were calculated for different cut off values of liver stiffness. Variable cut off values were also tested for different aetiologies. <h3>Results</h3> 150 patients were included in the study; 80 males and 70 females. The most common aetiology was alcohol related liver disease (ARLD) representing 39%, followed by non-alcoholic fatty liver disease (NAFLD) 19% and viral hepatitis 11%. Age range of our cohort was 22–90 years (average 61.7). 27 patients (18%) had oesophageal varices. Mean liver stiffness measurement was much higher (51.6 kPa) in the group with varices as compared to the group with no varices (31.9 kPa). LSM cut off value of 25 kPa showed sensitivity of 92.6% and specificity of 56.9% with positive predictive value of 32%. A lower cut off value of 21.5 kPa showed higher sensitivity (100%), but low positive predictive value of 30%. In our study no significant variations were observed between different aetiologies. <h3>Conclusion</h3> Transient elastography is a useful non invasive method for assessing patients with chronic liver disease. It allows us to stratify the degree of liver fibrosis and also to predict the risk of developing oesophageal varices. Patients with advanced fibrosis/cirrhosis with low LSM &lt; 21.5 kPa have a low risk of developing oesophageal varices and may avoid unnecessary endoscopy procedure. We recommend that all patients with LSM &gt; 21.5 kPa should undergo surveillance endoscopy for oesophageal varices. <h3>Disclosure of interest</h3> None Declared.
Termination initiated by the therapist: a countertransference storm
Authors: W W Weddington, J O Cavenar
Journal: American Journal of Psychiatry (1979)

Termination of psychotherapy has been infrequently examined in the literature and often ignored by many training programs. Not only are criteria and techniques for termination not often discussed, but termination as a therapeutic opportunity has been neglected. The authors present two cases of psychotherapy termination initiated by the therapist and point out that countertransference phenomena, potentially destructive, are the major aspect separating psychotherapy termination by mutual agreement and termination initiated by the therapist. Careful, regular, and attentive supervision for therapists in training is essential to counterbalance the intensified countertransference reactions involved.
P0527 : Performance of fibroscan XL probe with adapted measurement depth for liver stiffness measurement in morbidly obese patients
Authors: Y. Liu, F. Surroop, P. Bedossa, J. Aron-Wisnewsky, L. Sandrin, J. Tordjman, K. Clément, M. Sasso, V. Miette
Journal: Journal of Hepatology (2015)
Hb Leslie, an unstable hemoglobin due to deletion of glutaminyl residue beta 131 (H9) occurring in association with beta0-thalassemia, HbC, and HbS
Authors: CL Lutcher, JB Wilson, ME Gravely, PD Stevens, CJ Chen, JG Lindeman, SC Wong, A Miller, M Gottleib, TH Huisman
Journal: Blood (1976)
AB0560 ANCA-Associated Vasculitis in Patients with Primary SjÖgren's Syndrome: Detailed Analysis of 6 New Cases and 15 Cases from the Literature
Authors: D. Guellec, E. Cornec-Le Gall, M. Groh, E. Hachulla, A. Karras, P. Charles, B. Dunogue, S. Abad, V. Devauchelle-Pensec, L. Guillevin, A. Saraux, D. Cornec
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Primary Sjögren9s syndrome (pSS) is a systemic autoimmune disease characterized by B-cell hyperactivation. In some patients, multiple autoantibodies develop, including anti-neutrophil cytoplasmic antibody (ANCA), which could lead to the development of ANCA-associated vasculitis (AAV). <h3>Objectives</h3> To describe clinical presentation, therapy and prognosis of patients diagnosed with both pSS and AAV. <h3>Methods</h3> Nation-wide survey in France collecting information on cases of AAV associated with pSS. The study was completed by a systematic review of the literature. <h3>Results</h3> This work identified 6 new cases of coexisting pSS and AAV: 2 microscopic polyangiitis (MPA), 2 MPO-ANCA renal-limited AAV, 1 granulomatosis with polyangiitis (GPA), and 1 eosinophilic granulomatosis with polyangiitis (EGPA). The systematic literature search identified 15 previously published cases. Among the 21 patients, 18 were females. Mean age at diagnosis of AAV was 64±10 years with mean pSS duration of 76±122 months. All individuals with pre-existent pSS experienced at least one extra-glandular manifestation attributable to pSS before AAV diagnosis. p-ANCA with anti-MPO specificity were found in 80% (16/20), c-ANCA with anti-PR3 specificity in 9.5% (2/20) and isolated c-ANCA in 14.3% (3/21). Vasculitis involved kidneys (n=13), lungs (n=6), peripheral nerves (n=5), skin (n=5), central nervous system (n=2), small bowel (n=1), muscle (n=1), and sinuses (n=1). The mean follow-up duration of AAV was 20.5 (±31.1) months. A favourable response to treatment was observed in 76.2% of cases (16/21), stabilization in 19% of cases (4/21) and one death was reported. <h3>Conclusions</h3> This work shows that AAV may occur in patients with pSS. These are most commonly p-ANCA associated vasculitis with anti-MPO specificity. The AAV may reveal an underlying pSS or arise during its evolution. In this latter case, its occurrence appears to be correlated with extra-glandular manifestations of pSS. <h3>Disclosure of Interest</h3> None declared
Production of Malignancy &lt;italic&gt;in vitro&lt;/italic&gt;. XII. Behavior of Recovery Cultures&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Emma Shelton, Wilton R. Earle
Journal: JNCI Journal of the National Cancer Institute (1951)

Journal Article Production of Malignancy in vitro. XII. Behavior of Recovery Cultures Get access Emma Shelton, Emma Shelton Search for other works by this author on: Oxford Academic PubMed Google Scholar Wilton R. Earle Wilton R. Earle National Cancer Institute, National Institutes of Health, U. S. Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 4, February 1951, Pages 817–837, https://doi.org/10.1093/jnci/11.4.817 Published: 01 February 1951 Article history Received: 30 October 1950 Published: 01 February 1951